Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-11-15

Clinical Trial Update: A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia [Phase 2]

View source ↗

Summary

Allergan's Phase 2 trial of AGN-214868 for postherpetic neuralgia has completed, and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-214868

Snippet

Sponsor: Allergan | Conditions: Neuralgia, Postherpetic | Phase 2 | Status: COMPLETED | Results posted: 2013-11-15